Breast Cancer Trial, Recruiting NCT06559371 Sponsor: Kunwei Shen Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT06559371
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a woman aged 18 or older
  • You are able to carry out daily activities with little to no limitation (confirm with trial site)
  • You have been diagnosed with breast cancer confirmed through a tissue or cell sample
  • Tests have shown that cancer has spread to the lymph nodes in your armpit area
  • You have already completed at least 3 rounds of treatment given before surgery (such as chemotherapy) and are planning to have surgery
  • You are willing and able to sign a consent form to take part in the trial

Who may not be able to join:

  • Your cancer has spread to other parts of the body beyond the breast and nearby lymph nodes
  • You are unable to complete the planned course of treatment given before surgery
  • You are currently pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Xiaosong Chen, Shanghai Jiao Tong University, School of Medicine, Affiliated Ruijin Hospital

Phone: 86-21-64370045

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Kunwei Shen
Registry
ClinicalTrials.gov
Start date
30 August 2024
Est. completion
30 June 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Sensitivity and specificity of 68Ga FAPI PET/CT in predicting residual axillary lymph node lesions after neoadjuvant therapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov